Free Newsletter
Novartis decision hurts NexMed shares
Novartis will not submit a new drug application for NexMed's topical experimental treatment for nail fungus, and that decision is hurting NexMed's share prices. The drug developer saw shares drop several times throughout the day yesterday. According to Novartis, late stage clinical trials on the treatment, called NM100060, were the cause of the decision. The topical treatment is aimed at mild to moderate toenail fungus.
In 2005, Novartis took on all regulatory, manufacturing, commercialization and clinical development responsibilities for the treatment in an exclusive, worldwide $4 million licensing deal, which had potential to net NexMed up to $47 million.
NexMed is hoping to recover following a mid-2009 release of the results of a comparator study in Europe, according to the company's president and chief executive officer, Vivian Lu.
- see NexMed's release
- read the story at CNN Money
- find out more at Market Watch
Related Articles:
NexMed ED therapy draws a "non-approvable" letter
NexMed - Best Pharma Stocks of 2007
NexMed taps Berman as new CEO
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: